Synexus

Management buyout of Synexus seeks to expand global network of sites

Monday, February 23, 2015 01:56 PM

Synexus, one of the largest international investigative site networks, with 25 dedicated research centers in eight countries including the U.K., Germany, Poland and South Africa, has completed a management buyout with an eye toward expanding into the U.S., Asia and South America.

More... »


Synexus acquires South African site, expands global footprint

Wednesday, September 3, 2014 12:46 PM

Synexus, a U.K.-based site management organization, has expanded its global presence with the acquisition of a specialist clinical trial site close to Cape Town's international airport. This is its fourth dedicated research center in South Africa and brings Synexus’ global site count to 24, with three new centers opened in the last six months.

More... »


Synexus, Northumbria Healthcare partner

Monday, November 18, 2013 01:53 PM

Synexus has partnered with Northumbria HealthcareNHS Foundation Trust to establish a clinical research facility at Hexham General Hospital, in North East England.

More... »

Synexus opens regional center in Poland to support global clinical trials

Wednesday, October 30, 2013 09:05 AM

Synexus has opened a regional office for Eastern Europe in Poland, reflecting the company’s commitment to the region.

More... »

Synexus expands presence in South Africa

Wednesday, July 18, 2012 01:21 PM

Synexus has further expanded its global presence with the opening of a new in-patient facility in Pretoria, South Africa. Synexus now has a total of four sites in South Africa, which provide access to millions of patients.

More... »

Synexus aquires Osteomed of Poland

Wednesday, May 2, 2012 04:59 PM

Synexus, a global company that recruits and runs late phase clinical trials, has further strengthened its leadership position in Poland with the acquisition of Warsaw-based Osteomed for an undisclosed sum.

More... »

Synexus exceeds expectations in clinical trial recruitment

Tuesday, October 25, 2011 01:53 PM

Synexus’ Pretoria clinical research center has enrolled more patients than any other site across the world in a type 2 diabetes trial for Janssen Pharmaceuticals.

More... »

Synexus names Pilgrim chairman

Monday, October 17, 2011 01:01 PM

Alan Pilgrim has taken over as chairman of Synexus from Trevor Jones, who continues on the board as a director and becomes president of the Synexus’ Scientific advisory board.

More... »

Large SMOs Synexus and Radiant head to India seeking large pool of treatment-naïve patients

Monday, January 24, 2011 12:02 PM

Two large site management organizations (SMOs), Radiant Research and Synexus, are planning expansions into India.

More... »

Synexus sees clinical trials rise 25% in Hungary

Tuesday, August 24, 2010 07:00 AM

Synexus’ clinical trials activity in Hungary increased by 25% during the first half of 2010. The company’s Dedicated Research Centre has been operating in Hungary since 2006 and has become one of the company’s most successful CEE sites. The Budapest-based operation has been involved in more than 74 trials since being acquired by Synexus, and has randomized over 600 patients. Dr Erika Nemeth, Synexus’ country manager in Hungary, said the trend of more clinical trials being conducted in Hungary is set to continue: “The high standards of medical and research & development expertise in Hungary has resulted in high levels of participation in clinical trials and means that pharma and biotech companies remain keen to include Hungary as part of their global clinical trial programs.” The prevalence of chronic conditions including CVD and COPD among the Hungarian population, together with little preventative healthcare and healthcare education, means the treatment naïve population remains substantial and therefore attractive for clinical trials. Also, the pharmaceutical market in Hungary is set to increase significantly in the coming decade, encouraging the major players to establish a stronger and more proactive presence there before their new drugs come to market. Synexus CEO Michael Fort said the productivity of investigators, the attractive overhead costs and the world-renowned medical expertise and innovation in Hungary make it one of his company’s key areas for future development.

More... »


CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs